文献速递衰弱、肌少症与跌倒多重用药老年慢病共病管理

填补老年人新药评价的空白:IUPHAR老年委员会策略

Addressing the gaps in evaluation of new drugs for older adults: Strategies from the International Union of Basic and Clinical Pharmacology (IUPHAR) Geriatric Committee.
PubMed 文献 · J Am Geriatr Soc · 2024-03-14

国际基础与临床药理学联合会(IUPHAR)老年委员会提出从临床前到临床全研究谱系的药物开发与评价策略,强调老年人药物需考虑多病共存、多重用药、跌倒、认知障碍和衰弱等特征。委员会立场声明提出12条转化研究关键原则,建议衰弱应在基线和作为结局测量,并提及生理药代动力学-药效学建模和人工智能等技术的潜在应用。

要点

  • 老年人药物评价需关注衰弱、多病共存、多重用药、跌倒和认知障碍等特征。
  • 立场声明提出12条关键原则,建议衰弱在基线和作为结局测量。
  • 临床前模型应复制年龄、衰弱、暴露时长、共病和合并用药。

核心结论

  • 老年人药物开发与评价需超越年龄,纳入衰弱、多病共存、多重用药、跌倒和认知障碍等老年特征。
  • IUPHAR老年委员会提出覆盖转化研究谱系的12条关键原则,建议在基线和作为结局测量衰弱。

研究设计与样本

  • IUPHAR老年委员会立场声明,提出从临床前到全临床研究谱系的药物开发与评价策略。

主要发现

  • 临床前模型复制年龄、衰弱、暴露时长、共病和合并用药可能改善转化。
  • 提及生理药代动力学-药效学建模和人工智能等技术在老年个体化医疗中的潜在应用。
  • 概述了中低收入国家快速老龄化人群在医疗保健和临床试验方面的考量。

关键数值与推荐

  • 立场声明提出12条关键原则,覆盖转化研究谱系。
  • 在老年人可能为主要使用者的药物中,衰弱应在基线和作为结局测量。

临床怎么用

  • 老年人药物评价应将衰弱纳入基线和结局测量。
  • 临床前研究应模拟目标老年患者的年龄、衰弱、暴露时长、共病和合并用药。
  • 研究全程应纳入老年人、照护者和医疗保健提供者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The International Union of Basic and Clinical Pharmacology (IUPHAR) Geriatric Committee aims to improve the use of drugs in older adults and develop new therapeutic approaches for the syndromes and diseases of old age through advocacy, education, and research. In the present paper, we propose strategies relevant to drug development and evaluation, spanning preclinical and the full range of clinical studies. Drugs for older adults need to consider not only age, but also other characteristics common in geriatric patients, such as multimorbidity, polypharmacy, falls, cognitive impairment, and frailty. The IUPHAR Geriatric Committee's position statement on 'Measurement of Frailty in Drug Development and Evaluation' is included, highlighting 12 key principles that cover the spectrum of translational research. We propose that where older adults are likely to be major users of a drug, that frailty is measured at baseline and as an outcome. Preclinical models that replicate the age, frailty, duration of exposure, comorbidities, and co-medications of the proposed patients may improve translation. We highlight the potential application of recent technologies, such as physiologically based pharmacokinetic-pharmacodynamic modeling informed by frailty biology, and Artificial Intelligence, to inform personalized medicine for older patients. Considerations for the rapidly aging populations in low- and middle-income countries related to health-care and clinical trials are outlined. Involving older adults, their caregivers and health-care providers in all phases of research should improve drug development, evaluation, and outcomes for older adults internationally.

来源:J Am Geriatr Soc,查看原文。版权归原作者所有。

引用

  1. Hilmer SN, Schwartz J, Petrovic M, et al. Addressing the gaps in evaluation of new drugs for older adults: Strategies from the International Union of Basic and Clinical Pharmacology (IUPHAR) Geriatric Committee. J Am Geriatr Soc. 2024. PMID: 38485461. doi:10.1111/jgs.18826

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。